Treatment for Malignant Pheochromocytomas and Paragangliomas: 5&#160;Years of Progress. (Q54987382)

14 June 2018

title

Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress. (English)

1 reference

14 June 2018

1 reference

Paola Jimenez

1

1 reference

14 June 2018

Claudio Tatsui

2

1 reference

14 June 2018

Aaron Jessop

3

1 reference

14 June 2018

Sonali Thosani

4

1 reference

14 June 2018

Camilo Jimenez

5

1 reference

14 June 2018

publication date

28 October 2017

1 reference

14 June 2018

published in

Current Oncology Reports

1 reference

14 June 2018

volume

19

1 reference

14 June 2018

issue

12

1 reference

14 June 2018

page(s)

83

1 reference

14 June 2018

Biochemical diagnosis of pheochromocytoma: which test is best?

cites work

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Predictive characteristics of malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Predictors of recurrence in pheochromocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

SDH mutations establish a hypermethylator phenotype in paraganglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Pheochromocytoma and Paraganglioma Susceptibility Genes: Estimating the Associated Risk of Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Metastatic pheochromocytoma and paraganglioma: focus on therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

I-123 MIBG imaging and intraoperative localization of metastatic pheochromocytoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Changing paradigms in the treatment of malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Electrophysiological Studies to Detect Peripheral Neuropathy in Children Treated With Vincristine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Radionuclide therapy in neuroendocrine tumours: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Pheochromocytoma and paraganglioma: imaging characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Cabozantinib: a review of its use in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Lenvatinib: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Stereotactic body radiosurgery for spinal metastases: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Shifting paradigms in the treatment of metastatic spine disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Stereotactic body radiotherapy for spinal metastases: current status, with a focus on its application in the postoperative patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Reliability of the spinal instability neoplastic scale among radiologists: an assessment of instability secondary to spinal metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Reliability of the Spinal Instability Neoplastic Score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Vertebroplasty and kyphoplasty: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Short-segment percutaneous pedicle screw fixation with cement augmentation for tumor-induced spinal instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Single-stage posterior vertebrectomy and replacement combined with posterior instrumentation for spinal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Thoracic kyphotic deformity reduction with a distractible titanium cage via an entirely posterior approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Thoracic vertebrectomy and spinal reconstruction via anterior, posterior, or combined approaches: clinical outcomes in 91 consecutive patients with metastatic spinal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Reliability analysis of the epidural spinal cord compression scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

The NOMS framework: approach to the treatment of spinal metastatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

SDHBmutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-017-0643-0

The current place and indications of 131I-metaiodobenzylguanidine therapy in the era of peptide receptor radionuclide therapy: determinants to consider for evolving the best practice and envisioning a personalized approach

21 January 2018

1 reference

12 December 2020

Treatment of malignant pheochromocytoma with combination chemotherapy

1 reference

12 December 2020

High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions

1 reference

12 December 2020

Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience

1 reference

12 December 2020

10.1007/S11912-017-0643-0

Identifiers

DOI

1 reference

14 June 2018

1 reference

14 June 2018